Effects of pioglitazone and metformin on mitochondrial function evaluated with 31P MRS in type 2 DM.

Phase 4

• Conditions: type 2 diabetes

• Registration Number: JPRN-UMIN000000814
• Lead Sponsor: Kobe University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-10-01
• Study Completion: 2008-09-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1. Severe renal dysfunction(serum creatinine>2.0mg/dl) 2. Severe liver dysfunction(AST, ALT>50IU/ml) 3. Severe heart failure 4. History of hypersensitivity to pioglitazone or metformin 5. During the pregnancy or nursing 6. Arteriosclerosis obliterans (ASO) (ABI<0.9) 7. Poor control of plasma glucose (FPG>150mg/dl) 8. Inadequate to entry to this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Measurement of mitochondrial function of skeletal muscle before and after 24 weeks treatment with different insulin sensitizers.

Secondary Outcome Measures

Name	Time	Method
1. Measurement of the amount of visceral fat, IMCL and HLC before and after 24 weeks treatment. 2. Measurement of GIR before and after 24 weeks treatment. 3. Measurement of FPG, IRI, HbA1c, total-cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, FFA, adipocytokines before and after 24 weeks treatment. 4. Measurement of body weight and waist before and after 24 weeks treatment.